A review of enzyme induction of warfarin metabolism with recommendations for patient management

Pharmacotherapy

Volumn 17, Issue 5 I, 1997, Pages 917-928

  Cropp, Jacquelyn S ^a,b   Bussey, Henry I ^a,b  

^a UNIVERSITY OF TEXAS AT AUSTIN   (United States)

^b UNIVERSITY OF TEXAS HEALTH SCIENCE CENTER AT SAN ANTONIO   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMINOGLUTETHIMIDE; CARBAMAZEPINE; DICLOXACILLIN; GRISEOFULVIN; NAFCILLIN; PHENOBARBITAL; PHENYTOIN; RIFAMPICIN; SECOBARBITAL; WARFARIN;

ALCOHOL CONSUMPTION; ANTICOAGULATION; CLINICAL TRIAL; DOSE RESPONSE; DOSE TIME EFFECT RELATION; DRUG BLOOD LEVEL; DRUG EFFECT; DRUG METABOLISM; ENZYME ACTIVITY; ENZYME INDUCTION; HUMAN; MAJOR CLINICAL STUDY; PATIENT CARE; REVIEW; SMOKING; TREATMENT PLANNING;

ANIMALS; ANTICOAGULANTS; DRUG INTERACTIONS; ENZYME INDUCTION; HUMANS; WARFARIN;

EID: 0030824584     PISSN: 02770008     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (87)

1. Fihn S. Aiming for safe anticoagulation [editorial]. N Engl J Med 1995;333:54-5.
2. Hirsh J, Dalen JE, Deykin D, Poller L. Oral anticoagulants: mechanism of action, clinical effectiveness, and optical therapeutic range. Chest 1992;102(suppl):312s-26.
3. Park BK. Warfarin: metabolism and mode of action. Biochem Pharmacol 1988;37:19-27.
4. Campbell HA, Link KP. Studies on the haemorrhagic sweet clover disease. The isolation and crystallization of the haemorrhagic agent. J Biol Chem 1941;138:21-33.
5. Wells PS, Holbrook AM, Crowther NR, Hirsh J. Interactions of warfarin with drugs and food. Ann Intern Med 1994;121:676-83.
6. Porter RS, Sawyer WT. Warfarin. In: Evans WE, Schentag JJ, Jusko WJ, eds. Applied pharmacokinetics: principles of therapeutic drug monitoring. Vancouver: Applied Therapeutics, 1992:31-1-46.
7. Kearns PJ. Bioavailability of warfarin in a patient with short bowel syndrome. J Parenteral Enterai Nutr 1986;10:100.
8. Chan E, McLachlan AJ, Pegg M, MacKay AD, Cole RB, Rowland M. Disposition of warfarin enantiomers and metabolites in patients during multiple dosing with rac-warfarin. Br J Clin Pharmacol 1994;37:563-9.
9. Hermans JJR, Thijssen HHW. Human liver microsomal metabolism of the enantiomers of warfarin and acenocoumarol: P450 isozyme diversity determines the differences in their pharmacokinetics. Br J Pharmacol 1993;110:482-90.
10. Okey AB. Enzyme induction in the cytochrome P-450 system. Pharmacotherapy 1990;45:241-98.
11. Dupont. Coumadin (warfarin) package insert. Wilmington, DE; 1995.
12. O'Reilly RA. The stereoselective interaction of warfarin and metronidazole in man. N Engl J Med 1980;302:33-5.
13. Choonara IA, Cholerton S, Haynes BP, Breckenridge AM, Park BK. Stereoselective interaction between the R enantiomer of warfarin and cimetidine. Br J Clin Pharmacol 1986;21:271-7.
14. Duffield P, Duffield AM, Birkett DJ, Wade DN. Warfarin and warfarin-alcohol levels in anticoagulated patients. Aust N Z J Med 1979;9:534-7.
15. Wynne H, Cope L, Kelly P, Whittingham T, Edwards C, Kamali F. The influence of age, liver size, and enantiomer concentrations on warfarin requirements. Br J Clin Pharmacol 1995;40:203-7.
16. Hara K, Akiyama Y, Tajima T. Sex differences in the anticoagulant effects of warfarin. Jpn J Pharmacol 1994;66:387-92.
17. Pearce R, Greenway D, Parkinson A. Species differences and interindividual variation in liver microsomal cytochrome P450 2A enzymes: effects on coumarin, dicumarol, and testosterone oxidation. Arch Biochem Biophys 1992;298:211-25.
18. Goldberg DM. The expanding role of microsomal enzyme induction, and its implications for clinical chemistry. Clin Chem 1980;26:691-9.
19. Shimada T, Misono KS, Guengerich FP. Human liver microsomal cytochrome P-450 mephenytoin 4-hydroxylase, a prototype of genetic polymorphism in oxidative drug metabolism. J Biol Chem 1986;261:909-21.
20. Hansen JM, Siersboek-Nielsen K, Skovsted L. Carbamazepine-induced acceleration of diphenylhydantoin and warfarin metabolism in man. Clin Pharmacol Ther 1971;12:539-43.
21. Ross JRY, Beeley L. Interaction between carbamazepine and warfarin. Br Med J 1980;260:1415-16.
22. Whitfield JB, Moss DW, Neale G, Orme M, Breckenridge A. Changes in plasma γ-glutamyl transpeptidase activity associated with alterations in drug metabolism in man. Br Med J 1973;1:316-18.
23. Kendall AG, Boivin M. Warfarin-carbamazepine interaction [letter]. Ann Intern Med 1981;94:280.
24. Denbow CE, Fraser HS. Clinically significant hemorrhage due to warfarin-carbamazepine interaction [letter]. South Med J 1990;83:981.
25. Kerr BR, Thummel KE, Wurden CJ, et al. Human liver carbamazepine metabolism: role of CYP3A4 and CYP2C8 in 10,11epoxide formation. Biochem Pharmacol 1994;47: 1969-79.
26. Jerling M, Lindstom L, Bondessom, Bertilsson L. Fluvoxamine inhibition and carbamazepine induction of the metabolism of clozapine: evidence from a therapeutic drug monitoring service. Ther Drug Monit 1994;16:368-74.
27. Corn M. Effect of phenobarbital and glutethimide on biological half-life of warfarin. Thromb Diatherm Haemorrhage 1966;16:606-12.
28. Robinson DS, Sylwester D. Interaction of commonly prescribed drugs and warfarin. Ann Intern Med 1970;72:853-6.
29. MacDonald MG, Robinson DS, Sylwester D, Jaffe JJ. The effects of phenobarbital, chloral betaine, and glutethimide administration on warfarin plasma levels and hypoprothrombinemic responses in man. Clin Pharmacol Ther 1969;10:80-4.
30. Levy G, O'Reilly RA, Aggler PM, Keech GM. Pharmacokinetic analysis of the effect of barbiturate on the anticoagulant action of warfarin in man. Clin Pharmacol Ther 1970;11:372-7.
31. MacDonald MG, Robinson DS. Clinical observations of possible barbiturate interference with anticoagulation. JAMA 1968;204:95-8.
32. Antlitz AM, Tolentino M, Kosai MF. Effect of butabarbital on orally administered anticoagulants. Curr Ther Res 1968;10: 70-3.
33. Udall JA. Clinical implication of warfarin interactions with five sedatives. Am J Cardiol 1975;35:67-71.
34. O'Reilly RA, Trager WF, Motley CH, Howald W. Interaction of secobarbital with warfarin pseudoracemates. Clin Pharmacol Ther 1980;28:187-95.
35. Orme M, Breckenridge A. Enantiomers of warfarin and phenobarbital [letter]. N Engl J Med 1976;295:1482.
36. Shaw PM, Barnes TS, Cameron D, et al. Purification and characterization P-450 catalysing cyclosporin metabolism. Biochem J 1989;263:653-63.
37. Waxman DJ, Azaroff L. Phenobarbital induction of cytochrome P-450 gene expression. Biochem J 1992;281: 577-92.
38. MacKichan JJ. Pharmacokinetic consequences of drug displacement from blood and tissue proteins. Clin Pharmacokinet 1984;9(suppl 1):32-41.
39. Solomon GE, Hilgartner MW, Kutt H. Coagulation defects caused by diphenylhydantoin. Neurology 1972;22:1165-71.
40. Keith DA, Gallop PM. Phenytoin, hemorrhage, skeletal defects and vitamin K in the newborn. Med Hypotheses 1979;5: 1347-51.
41. DeVane CL. Pharmacogenetics and drug metabolism of newer antidepressant agents. J Clin Psychiatry 1994;55(suppl 12):38-45.
42. Veronese ME, Mackenzie PI, Doecke CJ, McManus ME, Miners JO, Birkett DJ. Tolbutamine and phenytoin hydroxylations by cDNA-expressed human liver cytochrome P450-2C9. Biochem Biophys Res Commun 1991;175:1112-18.
43. Hansen JM, Kristensen M, Skovsted L, Christensen LK. Dicoumarol-induced diphenylhydantoin intoxication. Lancet 1966;2:265-6.
44. Panegyes PK, Rischbieth RH. Fatal phenytoin warfarin interaction [letter]. Postgrad Med J 1991;67:98.
45. Nappi JM. Warfarin and phenytoin interaction [letter]. Ann Intern Med 1979;90:852.
46. Hansen JM, Sierbaek-Neilsen K, Kristensen M, Skovsted L, Christensen LK. Effect of diphenylhydantoin on the metabolism of dicoumarol in man. Acta Med Scand 1971;189:15-19.
47. Romankiewicz JA, Ehrman M. Rifampin and warfarin: a drug interaction. Ann Intern Med 1975;82:224-5.
48. Self TH, Mann RB. Interaction of rifampin and warfarin. Chest 1975;67:490-1.
49. Fox P. Warfarin-rifampicin interaction [letter]. Med J Aust 1982;1:60.
50. O'Reilly RA. Interaction of sodium warfarin and rifampin. Ann Intern Med 1974;81:337-40.
51. O'Reilly RA. Interaction of chronic daily warfarin therapy and rifampin. Ann Intern Med 1975;83:506-8.
52. Almog S, Martinowitz U, Halkin H, Bank HZ, Farfel Z. Complex interaction of rifampin and warfarin. South Med J 1988;81:1304-6.
53. Kolars JC, Schmiedlin-Ren P, Schuetz JD, Fang C, Watkins PB. Identification of rifampin-inducible P450IIIA4 (CYP3A4) in human small bowel enterocytes. J Clin Invest 1992;90: 1871-8.
54. Bachmann KA, Jauregui L. Use of single sample clearance estimates of cytochrome P450 substrates to characterize human hepatic CYP status in vivo. Xenobiotica 1993;23:307-15.
55. Heimark LD, Gibaldi M, Trager WF, O'Reilly RA, Goulart DA. The mechanism of the warfarin-rifampin drug interaction in humans. Clin Pharmacol Ther 1987;42:388-94.
56. Cullen SI, Catalano PM. Griseofulvin-warfarin antagonism. JAMA 1967;199:582-3.
57. Udall JA. Drug interference with warfarin therapy. Clin Med 1970;77:20-5.
58. Okino K, Weibert RT. Warfarin-griseofulvin interaction. Drug Intell Clin Pharm 1986;20:291-3.
59. Straughn AB, Meyer MC, Raghow G, Rotenberg K. Bioavailability of microsize and ultramicrosize griseofulvin products in man. J Pharmacokinet Biopharm 1980;8:347-62.
60. Qureshi GD, Reinders TP, Somori GJ, Evans HJ. Warfarin resistance with nafcillin therapy. Ann Intern Med 1984;100: 527-9.
61. Shovick VA, Rihn TL. Decreased hypoprothrombinemic response to warfarin secondary to the warfarin-nafcillin interaction. Drug Intell Clin Pharm 1991;25:598-600.
62. Davis RL, Berman W, Wernly JA, Kelly HW. Warfarin-nafcillin interaction. J Pediatr 1991;118:300-3.
63. Heilker GM, Fowler JW, Self TH. Possible nafcillin-warfarin interaction. Arch Intern Med 1994;154:822-4.
64. Fraser GL, Miller M, Kane K. Warfarin resistance associated with nafcillin therapy. Am J Med 1989;87:237-8.
65. Taylor AT, Pritchard DC, Goldstein AO, Fletcher JL. Continuation of warfarin-nafcillin interaction during dicloxacillin therapy. J Fam Pract 1994;39:182-5.
66. Krstenansky PM, Jones WN, Garewal HS. Effect of dicloxacillin sodium on the hypoprothrombinemic response to warfarin sodium. Clin Pharm 1987;6:804-6.
67. Jackson L, Homeida M, Roberts CJC. The features of hepatic enzyme induction with glutethimide in man. Br J Clin Pharmacol 1978;6:525-8.
68. Kvinssland S, Lonning PE, Ueland PM. Aminoglutethimide as an inducer of microsomal enzymes. 1. Pharmacological aspects. Breast Cancer Res Treat 1986;7(suppl):73-6.
69. Lonning PE. Aminoglutethimide enzyme induction: pharmacological and endocrinological implications. Cancer Chemother Pharmacol 1990;26:241-4.
70. Lonning PE, Kvinnsland S, Jahren G. Aminoglutethimide and warfarin. A new important drug interaction. Cancer Chemother Pharmacol 1984;12:10-12.
71. Thompson TA, Vermeulen JD, Wagner WE, LeSher AR. Aminoglutethimide bioavailability, pharmacokinetics, and binding to blood constituents. J Pharm Sci 1981;70:1040-3.
72. Lonning PE, Ueland PM, Kvinnsland S. The influence of a graded dose schedule of aminoglutethimide on the disposition of the optical enantiomers of warfarin in patients with breast cancer. Cancer Chemother Pharmacol 1986;17:177-81.
73. Jusko WJ. Influence of cigarette smoking on drug metabolism in man. Drug Metabol Rev 1979;9:221-36.
74. Hunt SN, Jusko WJ, Yurchak AM. Effect of smoking on theophylline disposition. Clin Pharmacol Ther 1976;19: 546-51.
75. Powell JR, Thiercelin JF, Vozeh S, Sansom L, Riegelman S. The influence of cigarette smoking and sex on theophylline disposition. Am Rev Respir Dis 1977;116:17-23.
76. Luczynska C, Wilson K. The clinical significance of the effects of cigarette smoking on drug disposition. Methods Find Exp Clin Pharmacol 1983;5:479-87.
77. Mitchell AA. Smoking and warfarin dosage [letter]. N Engl J Med 1972;287:1153-4.
78. Weiner B, Faraci PA, Fayad R, Swanson L. Warfarin dosage after prosthetic valve replacement: effect of smoking history. Drug Intell Clin Pharm 1984;18:904-6.
79. Bachmann K, Shapiro R, Fulton R, Carroll FT, Sullivan TJ. Smoking and warfarin disposition. Clin Pharmacol Ther 1979;25:309-15.
80. Kalow M, Tang B. Caffeine as a metabolic probe: exploration of the enzyme-inducing effect of cigarette smoking. Clin Pharmacol Ther 1991;49:44-8.
81. O'Reilly R. Lack of effect of mealtime wine on the hypoprothrombinemia of oral anticoagulants. Am J Med Sci 1979;277:189-94.
82. Wilkinson PK, Sedman AJ, Sakmar E. Fasting and nonfasting blood ethanol concentrations after repeated oral administration of ethanol to one adult male. J Pharmacokinet Biopharm 1977;5:41-52.
83. O'Reilly R. Lack of effect of fortified wine ingested during fasting and anticoagulant therapy. Arch Intern Med 1981;141:458-9.
84. Karlson B, Leijd B, Hellstrom K. On the influence of vitamin K-rich vegetables and wine on the effectiveness of warfarin treatment. Acta Med Scand 1986;220:347-50.
85. Kater RMH, Roggin G, Tobon F, Zieve P, Iber FL. Increased rate of clearance of drugs from the circulation of alcoholics. Am J Med Sci 1969;258:35-9.
86. Carroccio A, Wu D, Cederbaum AI. Ethanol increases content and activity of human cytochrome P4502E1 in a transduced HepG2 cell line. Biochem Biophys Res Commun 1994;203: 727-33.
87. Tsutsumi M, Lasker JM, Takahashi T, Lieber CS. In vivo induction of hepatic P4502E1 by ethanol: role of increased enzyme synthesis. Arch Biochem Biophys 1993;304:209-18.